Novartis Ag (NVS) Non-Current Assets (2009 - 2026)
Novartis Ag (NVS) posted Non-Current Assets of $94.7 billion for Q2 2026, up 17.63% sequentially from $80.5 billion in Q4 2025, and up 20.68% YoY from $78.5 billion in Q2 2025.
Novartis Ag (NVS) Non-Current Assets (2009 - 2026) Analysis & Trends
Novartis Ag has reported Non-Current Assets for 18 years, with the latest figure at $94.7 billion in Q2 2026.
- Quarterly Non-Current Assets rose 20.68% year-over-year to $94.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $145.2 billion (up 85.03% YoY) and the FY2025 annual result came in at $80.5 billion, up 10.96% from the prior year.
- Non-Current Assets grew to $94.7 billion in Q2 2026 per NVS's latest filing, from $80.5 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $94.7 billion in Q2 2026 and troughed at $69.5 billion in Q4 2023.
- A 5-year average of $78.9 billion and a median of $78.5 billion in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets dropped 15.41% in 2022, then increased 20.68% in 2026.
- Over 5 years, Non-Current Assets stood at $80.5 billion in 2022, then retreated by 13.76% to $69.5 billion in 2023, then increased by 4.43% to $72.5 billion in 2024, then climbed by 10.96% to $80.5 billion in 2025, then gained by 17.63% to $94.7 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $94.7 billion, $80.5 billion, and $78.5 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 113.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94.68 Bn |
| Dec 31, 2025 | 80.49 Bn |
| Jun 30, 2025 | 78.46 Bn |
| Dec 31, 2024 | 72.54 Bn |
| Jun 30, 2024 | 71.81 Bn |
| Dec 31, 2023 | 69.46 Bn |
| Jun 30, 2023 | 77.49 Bn |
| Dec 31, 2022 | 80.54 Bn |
| Jun 30, 2022 | 84.77 Bn |
| Dec 31, 2021 | 86.08 Bn |
| Jun 30, 2021 | 100.21 Bn |
| Dec 31, 2020 | 102.39 Bn |
| Jun 30, 2020 | 99.88 Bn |
| Dec 31, 2019 | 88.87 Bn |
| Jun 30, 2019 | 87.97 Bn |
| Dec 31, 2018 | 110.00 Bn |
| Jun 30, 2018 | 109.99 Bn |
| Dec 31, 2017 | 104.87 Bn |
| Sep 30, 2017 | -3.30 Bn |
| Jun 30, 2017 | -26.70 Bn |